Information Provided By:
Fly News Breaks for January 14, 2020
TDOC
Jan 14, 2020 | 08:30 EDT
Barclays analyst Steve Valiquette raised his price target for Teladoc Health to $95 from $80 while keeping an Equal Weight rating on the shares. Management provided "quite upbeat commentary" related to the core business as well as the recently announced acquisition of InTouch Health, Valiquette tells investors in a research note. Valuation keeps the analyst on the sidelines, however.